This retrospective registry across 11 European centres included 972 patients with cardiogenic shock supported by microaxial flow pumps; 340 (35.0%) required renal replacement therapy (RRT). The primary outcome was 180-day all-cause mortality, with survival censored at heart transplantation or durable left ventricular assist device implantation. After propensity score matching, estimated mortality was 59.0% with RRT versus 41.4% without RRT (HR 1.48, 95% CI 1.14–1.92). Higher baseline creatinine, obesity, norepinephrine use, and lactate ≥4 mmol/L at pump implantation were associated with RRT in multivariable analysis.
RRT was common and associated with higher 180-day mortality in pump-supported cardiogenic shock. These findings characterize prognosis but do not establish that RRT itself causes excess mortality.
Study limitation: Retrospective registry data remain vulnerable to residual confounding by shock severity despite propensity score matching.
AI-generated from the published abstract with automated source checks. For research discovery; consult the original paper before applying findings.